Compare KVHI & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | INO |
|---|---|---|
| Founded | 1978 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.4M | 133.4M |
| IPO Year | 1996 | 1999 |
| Metric | KVHI | INO |
|---|---|---|
| Price | $7.59 | $1.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 162.1K | ★ 4.7M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.33 | ★ 54.18 |
| EPS | ★ 0.04 | N/A |
| Revenue | $9,622,000.00 | ★ $42,220,086.00 |
| Revenue This Year | $28.90 | $20,156.19 |
| Revenue Next Year | $31.85 | $421.95 |
| P/E Ratio | $188.00 | ★ N/A |
| Revenue Growth | 3.82 | ★ 19.37 |
| 52 Week Low | $5.09 | $0.56 |
| 52 Week High | $13.00 | $2.86 |
| Indicator | KVHI | INO |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 64.40 |
| Support Level | $7.32 | $1.03 |
| Resistance Level | $7.67 | $1.79 |
| Average True Range (ATR) | 0.32 | 0.11 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 35.68 | 86.36 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.